| Place of Origin: | China |
|---|---|
| Brand Name: | HNB |
| Certification: | ISO |
| Model Number: | Pazufloxacin mesylate |
| Minimum Order Quantity: | 1KG |
| Price: | Negotiable |
| Packaging Details: | Aluminum foil bag |
| Delivery Time: | Usually7-10days |
| Payment Terms: | L/C, D/A, D/P, T/T, , MoneyGram |
| Supply Ability: | 5000kg/Month |
| CAS: | 163680-77-1 | Mf: | C17H19FN2O7S |
|---|---|---|---|
| MW: | 414.405 | Specification: | ≥98% |
| Einecs No.: | N/A | Appearance: | Yellow Powder |
| High Light: | Synthetic Quinolone Pazufloxacin mesylate,CAS 163680-77-1 Pazufloxacin mesylate,CAS 163680-77-1 anti infective drugs |
||
CAS 163680-77-1 Synthetic anti-infective drugs Quinolone Pazufloxacin mesylate Powder
|
Product Name |
Pazufloxacin mesylate |
|
Function |
APIs |
|
Specification |
99%Tech |
|
Chemical Name |
(3S)-10-(1-Aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid methanesulfonate (1:1) |
|
CAS No. |
|
|
Empirical Formula |
C17H19FN2O7S |
|
Toxicology |
Dangerous decomposition products: carbon monoxide, carbon dioxide, nitrogen oxides (NOx), hydrogen fluoride, sulfur oxides |
|
Applications |
Pazufloxacin (T-3761) mesylate is a quinolone antibiotic. |
|
Package |
1kg/bag,25kg/drum |
The Introductction of Pazufloxacin mesylate:
Pazufloxacin (T-3761) mesylate is a fluoroquinolone antibiotic.Target: AntibacterialPazufloxacin (T-3761), a new quinolone derivative, showed broad and potent antibacterial activity. T-3761 showed good efficacy in mice against systemic, pulmonary, and urinary tract infections with gram-positive and gram-negative bacteria, including quinolone-resistant Serratia marcescens and Pseudomonas aeruginosa. The in vivo activity of T-3761 was comparable to or greater than those of ofloxacin,norfloxacin, and tosufloxacin against most infection models in mice.
The Application & Function of Pazufloxacin mesylate:
This product is suitable for the following infections caused by sensitive bacteria:
(1) Secondary infections of chronic respiratory diseases, such as chronic bronchitis, diffuse bronchiolitis, bronchiectasis, emphysema, pulmonary interstitial fibrosis, bronchial asthma, old tuberculosis, etc.; Pneumonia, lung abscess;
(2) pyelonephritis, complex cystitis, prostatitis;
(3) burn wound infection, surgical wound infection;
(4) cholecystitis, cholangitis, liver abscess;
(5) intra-abdominal abscess and peritonitis;
(6) infection of reproductive organs, such as adnexitis and endometritis; Pelvic inflammatory disease.
Application:
The activities of T-3761 were lower than those of tosufloxacin against gram-positive bacterial systemic and pulmonary infections in mice but not against infections with methicillin-resistant Staphylococcus aureus [1]. T-3761 had a broad spectrum of activity and had potent activity against gram-positive and -negative bacteria. The MICs of T-3761 against 90% of the methicillin-susceptible Staphylococcus aureus, methicillin-susceptible and -resistant Staphylococcus epidermidis, and Clostridium spp. tested were 0.39 to 6.25 micrograms/ml. The MBCs of T-3761 were either equal to or twofold greater than the MICs. The 50% inhibitory concentrations of T-3761 for DNA gyrases isolated from E. coli and P. aeruginosa were 0.88 and 1.9 micrograms/ml, respectively
The COA of Pazufloxacin mesylate
